Literature DB >> 22331948

Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer.

Joline S W Lind1, Suresh Senan, Egbert F Smit.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22331948     DOI： 10.1200/JCO.2011.38.4552

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  23 in total

Review 1.  Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer.

Authors:  Joshua D Palmer; Nicholas G Zaorsky; Matthew Witek; Bo Lu
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

Review 2.  Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma.

Authors:  Bhaskar Bhardwaj; Swaroop Revannasiddaiah; Himanshu Bhardwaj; Sree Balusu; Ali Shwaiki
Journal:  Ann Transl Med       Date:  2016-02

Review 3.  Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).

Authors:  F Couñago; A Rodríguez; P Calvo; J Luna; J L Monroy; B Taboada; V Díaz; N Rodríguez de Dios
Journal:  Clin Transl Oncol       Date:  2016-04-22       Impact factor: 3.405

4.  Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy.

Authors:  Kalliopi Domvri; Kaid Darwiche; Paul Zarogoulidis; Konstantinos Zarogoulidis
Journal:  Transl Lung Cancer Res       Date:  2013-08

5.  Combination of Palliative Thoracic Radiotherapy With Bevacizumab for Stage IV Nonsquamous NSCLC: Is There Any Impact of Time Interval on Survival?

Authors:  Weigang Xiu; Xiaotong Guo; Min Yu; Yanying Li; Yong Xu; Jiang Zhu; Jingjing Luo
Journal:  Clin Med Insights Oncol       Date:  2022-06-24

6.  New paradigms and future challenges in radiation oncology: an update of biological targets and technology.

Authors:  Stanley L Liauw; Philip P Connell; Ralph R Weichselbaum
Journal:  Sci Transl Med       Date:  2013-02-20       Impact factor: 17.956

Review 7.  Emerging developments of chemoradiotherapy in stage III NSCLC.

Authors:  Allan Price
Journal:  Nat Rev Clin Oncol       Date:  2012-08-28       Impact factor: 66.675

8.  A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321.

Authors:  Yujie Zhao; Nathan R Foster; Jeffrey P Meyers; Sachdev P Thomas; Donald W Northfelt; Kendrith M Rowland; Bassam I Mattar; David B Johnson; Julian R Molina; Sumithra J Mandrekar; Steven E Schild; James D Bearden; Marie-Christine Aubry; Alex A Adjei
Journal:  J Thorac Oncol       Date:  2015-01       Impact factor: 15.609

Review 9.  Anticancer therapy and lung injury: molecular mechanisms.

Authors:  Li Li; Henry Mok; Pavan Jhaveri; Mark D Bonnen; Andrew G Sikora; N Tony Eissa; Ritsuko U Komaki; Yohannes T Ghebre
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-23       Impact factor: 4.512

10.  Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead.

Authors:  M Mangoni; M-C Vozenin; G Biti; E Deutsch
Journal:  Br J Cancer       Date:  2012-06-12       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.